The document this correction applies to
Timely disclosureWhat was corrected and how
A subsequent correction by the company to the contents of an already published filing.
Financial Results Presentation for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026
Open the original documentP9. The red-outlined area in the upper chart showing the progress of the clinical trial for TMS-007 (JX10)
| Item | Details |
|---|---|
| Disclosure subject to correction | Financial Results Presentation for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026 |
| Original disclosure date | 14 August 2026 |
| Location of correction | P9. The red-outlined area in the upper chart showing the progress of the clinical trial for TMS-007 (JX10) |
| Details of correction | Deletion of the red-outlined area in the upper chart |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The correction is explained, but no specific reason for the correction is provided.